Wavegate Corporation Announces $26 Million Series A Funding Round Led by UCEA Capital Partners Ltd.

LAKE CHARLES, La., Dec. 10, 2024 /PRNewswire/ — Wavegate Corporation, a pioneering developer of neuromodulation technology for chronic pain management, has secured a lead investor in their $26 million Series A funding round led by UCEA Capital Partners Ltd., a London-based investment firm. This financing will accelerate the development of Wavegate’s proprietary Ellipse platform, featuring StimuLux technology, designed to provide breakthrough therapeutic solutions for chronic pain patients.

Wavegate Corporation has secured led investor UCEA Capital Partners Ltd. for its $26 million Series A funding round

Wavegate’s Ellipse spinal cord stimulator uses optical reflectometry to provide closed-loop adaptive modulation, uniquely adjusting stimulation in real-time based on spinal cord movement. This technology, which received FDA Breakthrough Device designation, offers significant potential to improve the lives of chronic pain sufferers by maintaining consistent pain relief across a range of patient activities using either paresthesia-based or paresthesia-free neuromodulation. Wavegate also recently achieved successful first-in-human data, further validating the clinical promise of its Ellipse platform.

“Securing this funding represents a pivotal moment for Wavegate as we continue to push the boundaries in neuromodulation technology,” said Dr. Erich Wolf, CEO of Wavegate Corporation. “UCEA’s investment validates the potential of our innovations and supports our vision of advancing effective, patient-centered pain management solutions.”

The investment by UCEA Capital Partners aligns with its strategic focus on supporting transformative healthcare technologies. “Wavegate’s approach to neuromodulation reflects exactly the type of high-impact, innovation-driven opportunity we seek to champion. We are thrilled to support their journey in addressing a critical area of unmet medical need,” noted Joao Teixeira, Chairman of UCEA Capital Partners Ltd.

The Series A funding will be instrumental in expanding Wavegate’s R&D efforts, clinical trials, and preparations for regulatory approvals, marking a significant step forward for the company as it progresses toward commercialization.

For more information on Wavegate Corporation, visit wavegate.us.

Media Contact:
Marla Miller, JD, LLM
Corporate Secretary
marla@wavegate.us
+1-337-419-1360

View original content to download multimedia:https://www.prnewswire.com/news-releases/wavegate-corporation-announces-26-million-series-a-funding-round-led-by-ucea-capital-partners-ltd-302328197.html

SOURCE Wavegate Corporation

Staff

Recent Posts

The Doctor and The Athlete: Powerhouse Duo Disrupts Functional Beverage Market with Science-Backed “Happiness”

TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- Happy Panda announces its official market launch with a…

5 hours ago

FUGO Precision 3D to Debut Revolutionary Centrifugal 3D Printing Technology with Live Demonstrations at LMT LAB DAY Chicago 2026

GARDENA, Calif., Feb. 2, 2026 /PRNewswire/ -- FUGO Precision 3D, developer of the world's first all-in-one…

5 hours ago

The Micro-Mechanics of Modern Oral Care

OXNARD, CA / ACCESS Newswire / February 2, 2026 / Quality Dental Services functions as…

8 hours ago

Dr. Shahrooz Yazdani Launches $6M Dental Practice Seminar Series to Help Owners Break Free from Burnout

Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…

11 hours ago

New Aura and UNC-Chapel Hill Study Finds One in Three Kids Have Accessed GenAI Apps

BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…

11 hours ago

‘Breathable’ Launches to Bring Hope and Humanity Back to Mental Health Care

New online network makes it simple, affordable and stigma-free to connect with licensed therapistsDETROIT, Feb.…

11 hours ago